Predictive importance of testing of polymorphic loci Arg72Pro exon 4 antioncogene TP53 in patients with non-hodgking lymphomas

The frequency of Arg72Pro exon 4 antioncogene ТР53 genotypes, as well as their association with the 5-year survival in patients with aggressive and indolent non-Hodgkin’s lymphoma (NHL) variants was studied. The statistically significant (p = 0.040) reduction in disease-free survival in patients with aggressive NHL and the Arg/Arg genotype (25 %) when compared with Arg/Pro and Pro/Pro patients (68,8 %) has been revealed. Thus, the testing of single nucleotide polymorphism Arg72Pro in exon 4 gene ТР53 may have a predictive importance for prognosis of survival of patients with aggressive non-Hodgkin’s lymphoma.

1. Berezina O.V., Vayner A.S., Voropayeva Ye.N. et al. // Sibirskoye meditsinskoye obozreniye. 2011. (3). 22–26. (in Russian)

2. Voropayeva Ye.N., Skvortsova N.V., Voyevoda M.I., Tarnovskiy R.V. // Byulleten' Sibirskogo Otdeleniya Rossiyskoy Akademii Meditsinskikh Nauk. 2011. (2). 26–30. (in Russian)

3. Pospelova T.I., Voropayeva Ye.N., Voyevoda M.I., Berezina O.V. // Gematologiya i transfuziologiya 2010. 55. (1). 11–17. (in Russian)

4. Cerhan J.R. Host genetics in follicular lymphoma // Best Pract. Res. Clin. Haematol. 2011. 24. (2). 121–134.

5. Havranek O., Spacek M., Hubacek P. et al. No association between the TP53 codon 72 polymorphism and risk or prognosis of Hodgkin and non-Hodgkin lymphoma // Leuk. Res. 2011. 35. (8). 1117–1119.

6. Hsieh L.L., Huang T.H., Chen I.H. et al. p53 polymorphisms associated with mutations in and loss of heterozygosity of the p53 gene in male oral squamous cell carcinomas in Taiwan // Br. J. Cancer. 2005. 92. (1). 30–35.

7. Kim H.N., Yu L., Kim N.Y. et al. Association with TP53 codon 72 polymorphism and the risk of non-Hodgkin lymphoma // Am. J. Hematol. 2010. 85. (10). 822–824.

8. Kochethu G., Delgado J., Pepper C. et al. Two germ line polymorphisms of the tumour suppressor gene p53 may influence the biology of chronic lymphocytic leukaemia // Leuk. Res. 2006. 30. (9). 1113–1118.

9. Lahiri O., Harris S., Packham G., Howell M. p53 pathway gene single nucleotide polymorphisms and chronic lymphocytic leukemia // Cancer Genet. Cytogenet. 2007. 179. (1). 36–44.

10. Majid A., Richards T., Dusanjh P. et al. TP53 codon 72 polymorphism in patients with chronic lymphocytic leukaemia: identification of a subgroup with mutated IGHV genes and poor clinical outcome // Br. J. Haematol. 2011. 153. 529–540.

11. Mitra S., Misra С., Singh R.K. et al. Association of specific genotype and haplotype of p53 gene with cervical cancer in India // J. Clin. Pathol. 2005. 58. 26–31.

12. Sturm I., Bosanquet A.G., Hummel M. et al. TP53 codonon 72 polymorphic variants of p53 are not related to drug resistance and disease prognosis // BMC Cancer. 2005. 5. 105.

13. Tada M., Furuuchi K., Kaneda M. et al. Inactivate the remaining p53 allele or the alternate p73? Preferential selection of the Arg72 polymorphism in cancers with recessive p53 mutants but not transdominant mutants // Cancerogenesis. 2001. 22. (3). 515–517.

14. Weiner A.S., Beresina O.V., Voronina E.N. et al. Polymorphisms in folate-metadolizing genes and risk of non-Hodgkin’s lymphoma // Leuk. Res. 2011. 35. 508–515.

15. Wrench D., Waters R., Carlotti E. et al. Clinical relevance of MDM2 SNP 309 and TP53 Arg72Pro in follicular lymphoma // Haematol. 2009. 94. (1). 148–150.

Voropaeva E.N. – candidate of medical sciences, researcher of laboratory for molecular genetic researches of therapeutic diseases

Berezina O.V. – assistant of the chair for therapy, hematology and blood transfusiology, e-mail: ovberezina@mail.ru

Ovchinnikov V.S. – clinical resident of the chair for therapy, hematology and blood transfusiology, post_gem@mail.ru

Voevoda M.I. – corresponding member of RAMS, director

Pospelova T.I. – doctor of medical sciences, professor, head of the chair for therapy, hematology and transfusiology, e-mail: post_gem@mail.ru